| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | AT7867 | CTRPv2 | pan-cancer | AAC | -0.079 | 0.03 |
| mRNA | PLX4720 | GDSC1000 | pan-cancer | AAC | -0.068 | 0.03 |
| mRNA | Z-LLNle-CHO | GDSC1000 | pan-cancer | AAC | -0.11 | 0.03 |
| mRNA | JW-7-52-1 | GDSC1000 | pan-cancer | AAC | -0.12 | 0.03 |
| mRNA | EHT 1864 | GDSC1000 | pan-cancer | AAC | -0.075 | 0.03 |
| mRNA | Erlotinib | CTRPv2 | pan-cancer | AAC | 0.076 | 0.03 |
| mRNA | BRD-K97651142 | CTRPv2 | pan-cancer | AAC | -0.081 | 0.03 |
| mRNA | Doxorubicin | gCSI | pan-cancer | AAC | -0.12 | 0.03 |
| mRNA | Bortezomib | GDSC1000 | pan-cancer | AAC | -0.11 | 0.03 |
| mRNA | Vandetanib | CTRPv2 | pan-cancer | AAC | 0.079 | 0.03 |